Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | MC4R | P32245 | 8/20 | 0.46 |
| ▸ | MC1R | Q01726 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13529191 | 0.81 | LMNA (0.46) | OPRD1OPRK1OPRM1OPRL1MC4R | |
| SCHEMBL10900699 | 0.81 | OPRD1 (0.53) | OPRD1OPRK1OPRM1OPRL1HRH3 | |
| SCHEMBL13529174 | 0.81 | CCR3 (0.55) | OPRD1OPRK1MC4R | |
| SCHEMBL11590781 | 0.74 | RARB (0.51) | — | |
| SCHEMBL12513620 | 0.73 | MC4R (0.65) | OPRD1OPRK1OPRM1OPRL1HRH3 | |
| SCHEMBL20425879 | 0.73 | RARB (0.50) | — | |
| SCHEMBL860020 | 0.71 | RARB (0.49) | — | |
| SCHEMBL10677115 | 0.70 | CHRM2 (0.70) | OPRD1OPRK1OPRM1HRH3MC4R | |
| SCHEMBL2237570 | 0.70 | HPGD (0.46) | OPRD1HRH3 | |
| SCHEMBL22563037 | 0.70 | RARB (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | OPRD1 4428/4885OPRK1 1864/4885OPRM1 4649/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | OPRD1 4212/4885OPRK1 4042/4885OPRM1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.